Novel anticancer agents for multiple myeloma: A review of the evidence for their therapeutic and economic value

Expert Review of Anticancer Therapy

Volumn 12, Issue 6, 2012, Pages 839-854

  Gaultney, Jennifer G ^a   Redekop, William K ^a   Sonneveld, Pieter ^b   Uyl de Groot, Carin A ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

bortezomib; cost effectiveness; economic; efficacy; lenalidomide; multiple myeloma; patient reported outcomes; quality of life; review; thalidomide

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

ANEMIA; ANOREXIA; BONE MARROW SUPPRESSION; BRADYCARDIA; CANCER COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ECONOMIC ASPECT; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HERPES ZOSTER; HUMAN; HYPERCALCEMIA; INFECTION; MENTAL DISEASE; MONOTHERAPY; MULTIPLE MYELOMA; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; REVIEW; SOMNOLENCE; SPINAL CORD COMPRESSION; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; HUMANS; MULTIPLE MYELOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84862877588     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.42     Document Type: Review

References (88)

1. McCabe C, Bergmann L, Bosanquet N et al. Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. Ann. Oncol. 20(3), 403-412 (2009). Describes the challenges payers face to guarantee access to novel anticancer agents.
2. Garber AM, McClellan MB. Satisfaction guaranteed - 'payment by results' for biologic agents. N. Engl. J. Med. 357(16), 1575-1577 (2007). Describes the 'pay for performance'agreement between the NHS and the manufacturer of bortezomib, which is an example of the types of agreements payers are instituting to provide access to expensive drugs while also managing payment for ineffective treatment.
3. Anderson KC. Lenalidomide and thalidomide: mechanisms of action -similarities and differences. Semin. Hematol. 42(Suppl. 4), S3-S8 (2005).
4. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8(6), 508-513 (2003).
5. Fuchs SY. The role of ubiquitin-proteasome pathway in oncogenic signaling. Cancer Biol. Ther. 1(4), 337-341 (2002).
6. Richardson PG, Hideshima T, Mitsiades C, Anderson KC. The emerging role of novel therapies for the treatment of relapsed myeloma. J. Natl Compr. Cancer Netw. 5(2), 149-162 (2007).
7. Armoiry X, Fagnani F, Benboubker L et al. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study. J. Clin. Pharm. Ther. 36(1), 19-26 (2011). Provides data from real-world clinical practice to show that the costs of treating multiple myeloma are increasing, especially on account of the high acquisition costs of novel agents.
8. Bonkowski J, Vermeulen LC, Kolesar JM. The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes. J. Oncol. Pharm. Pract. 16(4), 223-232 (2009).
9. Knox C, Law V, Jewison T et al. Drug Bank 3.0: a comprehensive resource for 'omics' research on drugs. Nucl. Acids Res. 39(Database issue), D1035-D1041 (2011).
10. Mitsiades CS, Hideshima T, Chauhan D et al. Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin. Hematol. 46(2), 166-175 (2009).
11. Drummond MF, Schulpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes (Third Edition). Oxford University Press, Oxford, UK (2005).
12. Palumbo A, Attal M, Roussel M. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Clin. Cancer Res. 17(6), 1253-1263 (2011).
13. Hulin C, Facon T, Rodon P et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J. Clin. Oncol. 27(22), 3664-3670 (2009).
14. Ludwig H, Hajek R, Tothova E et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 113(15), 3435-3442 (2009).
15. Palumbo A, Bringhen S, Caravita T et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367(9513), 825-831 (2006).
16. Palumbo A, Bringhen S, Liberati AM et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 112(8), 3107-3114 (2008).
17. Waage A, Gimsing P, Fayers P et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 116(9), 1405-1412 (2010).
18. Wijermans P, Schaafsma M, Termorshuizen F et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 study. J. Clin. Oncol. 28(19), 3160-3166 (2010).
19. Mateos MV, Richardson PG, Schlag R et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the Phase III VISTA trial. J. Clin. Oncol. 28(13), 2259-2266 (2010).
20. San Miguel JF, Schlag R, Khuageva NK et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359(9), 906-917 (2008).
21. Mateos MV, Oriol A, Martinez-Lopez J et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 11(10), 934-941 (2010).
22. Palumbo A, Bringhen S, Rossi D. Bortezomib - melphalan - prednisone - thalidomide followed by maintenance with bortezomib - thalidomide versus bortezomib - melphalan-prednisone for initial treatment of multiple myeloma: a randomised controlled trial. J. Clin. Oncol. 28(34), 5101-5109 (2010).
23. Zonder JA, Crowley J, Hussein MA et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood 116(26), 5838-5841 (2010).
24. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. 24(3), 431-436 (2006).
25. Rajkumar SV, Rosinol L, Hussein M et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J. Clin. Oncol. 26(13), 2171-2177 (2008).
26. Facon T, Mary JY, Hulin C et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370(9594), 1209-1218 (2007).
27. Barlogie B, Pineda-Roman M, van Rhee F et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 112(8), 3115-3121 (2008).
28. Barlogie B, Tricot G, Anaissie E et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N. Engl. J. Med. 354(10), 1021-1030 (2006).
29. Lokhorst HM, van der Holt B, Zweegman S et al. A randomized Phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 115(6), 1113-1120 (2010).
30. Spencer A, Prince HM, Roberts AW et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J. Clin. Oncol. 27(11), 1788-1793 (2009).
31. Harousseau JL, Attal M, Avet-Loiseau H et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-2001 Phase III trial. J. Clin. Oncol. 28(30), 4621-4629 (2010).
32. Cavo M, Tacchetti P, Patriarca F et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised Phase 3 study. Lancet 376(9758), 2075-2085 (2010).
33. Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352(24), 2487-2498 (2005).
34. Richardson PG, Sonneveld P, Schuster M et al. Extended follow-up of a Phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 110(10), 3557-3560 (2007).
35. Orlowski RZ, Nagler A, Sonneveld P et al. Randomized Phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J. Clin. Oncol. 25(25), 3892-3901 (2007).
36. Mikhael JR, Belch AR, Prince HM et al. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global Phase 3b expanded access program. Br. J. Haematol. 144(2), 169-175 (2008).
37. Weber DM, Chen C, Niesvizky R et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357(21), 2133-2142 (2007).
38. Dimopoulos M, Spencer A, Attal M et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N. Engl. J. Med. 357(21), 2123-2132 (2007).
39. Dimopoulos MA, Chen C, Spencer A et al. Long-term follow-up on overall survival from the MM-009 and MM-010 Phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23(11), 2147-2152 (2009).
40. Castaneda CP, Brandenburg NA, Bwire R, Burton GH, Zeldis JB. Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients. J. Clin. Oncol. 27(1), 156-157 (2009).
41. Verelst SGR, Termorshuizen F, Uyl-de Groot CA et al. Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial. Ann. Hematol. 90(12), 1427-1439 (2011).
42. Dubois D, Dhawan R, van de Velde H et al. Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. J. Clin. Oncol. 24(6), 976-982 (2006).
43. Lee SJ, Richardson PG, Sonneveld P et al. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br. J. Haematol. 143(4), 511-519 (2008).
44. Mehta J, Duff SB, Gupta S. Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma. Managed Care Interf. 17(9), 52-61 (2004).
45. Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Lothgren M. The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. Eur. J. Haematol. 85(6), 484-491 (2010).
46. Moller J, Nicklasson L, Murthy A. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib. J. Med. Econ. 14(6), 690-697 (2011).
47. Zeigler BP, Praehofer H, Kim TG. Theory of Modeling and Simulation: Integrating Discrete Event and Continuous Complex Dynamic Systems (2nd Edition). Academic Press, CA, USA (2000).
48. Van Agthoven M, Segeren CM, Buijt I et al. A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised Phase III study. Eur. J. Cancer 40(8), 1159-1169 (2004).
49. Rowen D, Brazier J, Young T et al. Deriving a preference-based measure for cancer using the EORTC QLQ-C30. Value Health 14(5), 721-731 (2011).
50. Mitsiades CS, Davies FE, Laubach JP et al. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J. Clin. Oncol. 29(14), 1916-1923 (2011). Up-to-date description of the paradigm shift in the treatment of multiple myeloma.
51. Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Stat. Med. 9(11), 1259-1276 (1990).
52. Simpson KN, Strassburger A, Jones WJ, Dietz B, Rajagopalan R. Comparison of Markov model and discrete-event simulation techniques for HIV. Pharmacoeconomics 27(2), 159-165 (2009).
53. Heeg BM, Damen J, Buskens E, Caleo S, de Charro F, van Hout BA. Modelling approaches: the case of schizophrenia. Pharmacoeconomics 26(8), 633-648 (2008).
54. Moreau P, Attal M, Pegourie B et al. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-2001 trial. Blood 117(11), 3041-3044 (2010).
55. Niesvizky R, Richardson PG, Rajkumar SV et al. The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, Phase 3 APEX trial in relapsed multiple myeloma. Br. J. Haematol. 143(1), 46-53 (2008).
56. Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 114(15), 3139-3146 (2009).
57. Gartlehner G, Moore CG. Direct versus indirect comparisons: a summary of the evidence. Int. J. Technol. Assess. Health Care 24(2), 170-177 (2008).
58. Siegel DSD, Martin T, Wang M et al. PX-171-003-A1, an open-label, single-arm, Phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): long-term follow-up and subgroup analysis. Presented at: American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 3-7 June 2011.
59. Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 87(1), 78-88 (2012).
60. Rajkumar SV, Jacobus S, Callander NS et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 11(1), 29-37 (2010).
61. Dimopoulos MA, Richardson PG, Brandenburg N et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 119(12), 2764-2767 (2012).
62. Landgren O, Thomas A, Mailankody S. Myeloma and second primary cancers. N. Engl. J. Med. 365(23), 2241-2242 (2011).
63. Mahindra A, Cirstea D, Raje N. Novel therapeutic targets for multiple myeloma. Fut. Oncol. 6(3), 407-418 (2010). Describes the new agents in the pipeline for the treatment of multiple myeloma that are expected to be on the market in the coming years.
64. Schey S, Ramasamy K. Pomalidomide therapy for myeloma. Expert Opin. Invest. Drugs 20(5), 691-700 (2011).
65. Khan ML, Stewart AK. Carfilzomib: a novel second-generation proteasome inhibitor. Fut. Oncol. 7(5), 607-612 (2011).
66. Lacy MQ, Hayman SR, Gertz MA et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J. Clin. Oncol. 27(30), 5008-5014 (2009).
67. Mikhael JR, Rajkumar V, Roy V et al. Efficacy of pomalidomide plus low-dose dexamethasone in multiple myeloma patients despite previous use of lenalidomide. Presented at: American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 3-7 June 2011.
68. Stewart AK, Kaufman JL, Jakubowiak AJ et al. The effect of carfilzomib (CFZ) in patients (Pts) with bortezomib (BTZ)- naive relapsed or refractory multiple myeloma (MM): updated results from the PX-171-004 study. Presented at: American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA, 3-7 June 2011.
69. Dimopoulos MA, Jagannath S, Yoon SS et al. Vantage 088: vorinostat in combination with bortezomib in patients with relapsed/refractory multiple myeloma: results of a global, randomized Phase 3 trial. Presented at: American Society of Hematology Annual Meeting. San Diego, CA, USA, 10-13 December 2011.
70. Richardson PG, Wolf J, Jakubowiak A et al. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter Phase I/II trial. J. Clin. Oncol. 29(32), 4243-4249 (2011).
71. Wolf JL, Jakubowiak AJ, Zonder JA et al. Perifosine plus bortezomib and dexamethasone in relapsed / refractory multiple myeloma patients previously treated with bortezomib: final results of a Phase I/II trial. Presented at: American Society of Hematology Annual Meeting. San Diego, CA, USA, 10-13 December 2011.
72. Wolf JL, Siegel D, Goldschmidt H et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk. Lymphoma doi:10.3109/10428194.661175 (2012) (Epub ahead of print).
73. Offidani M, Polloni C, Cavallo F et al. Phase II study of melphalan, thalidomide and prednisone (MPT) combined with oral panobinostat in patients with relapsed/refractory MM. Leuk. Lymphoma doi:10.3109/10428194.664844 (2012) (Epub ahead of print).
74. Jakubowiak AJ, Benson DM, Bensinger W et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J. Clin. Oncol. doi:10.1200/JCO.37.7069 (2012) (Epub ahead of print).
75. Jagannath S, Dimopoulos MA, Lonial S. Combined proteasome and histone deacetylase inhibition: a promising synergy for patients with relapsed/refractory multiple myeloma. Leuk. Res. 34(9), 1111-1118 (2010). Demonstrated the synergy of combination therapy for multiple myeloma that consists of more than one novel agent.
76. Korde N, Kristinsson SY, Landgren O. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. Blood 117(21), 5573-5581 (2011).
77. Barlogie B, van Rhee F, Shaughnessy JD Jr et al. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 112(8), 3122-3125 (2008).
78. Mateos MV, Lopez-Corral L, Hernandez MT et al. Multicenter, randomized, open-label, Phase III trial of lenalidomide-dexamethasone (len/dex) vs therapeutic abstention in smoldering multiple myeloma at high risk of progression to symptomatic MM: results of the first interim analysis. Presented at: American Society of Hematology Annual Meeting. San Diego, CA, USA, 10-13 December 2011.
79. Johnson SK, Heuck CJ, Albino AP et al. The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma. Int. J. Hematol. 94(4), 321-333 (2011). Review of gene-expression profiling for risk stratification in multiple myeloma and its impact on clinical decision-making and drug design.
80. European Central Bank. Statistical Data Warehouse. This online database provides historical exchange rates for conversion of foreign currencies to Euros. http://sdw.ecb.europa.eu (Accessed 27 October 2011)
81. Evidence Review Group Report for NICE's Single Technology Appraisal process. Bortezomib for the treatment of multiple myeloma patients (July 2006). www.hta.ac.uk/erg/reports/1637.pdf (Accessed 27 October 2011)
82. Evidence Review Group Report for NICE's Single Technology Appraisal process. The clinical and cost-effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy: an evidence review of the submission from Celgene (October 2008). www.hta.ac.uk/erg/reports/ 1746.pdf (Accessed 27 October 2011)
83. Celgene Corporation. A Phase III, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma. http://clinicaltrials.gov/show/NCT01311687 (Accessed 12 March 2012)
84. Onyx Therapeutics, Inc. Phase III Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Versus Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma. http://clinicaltrials.gov/show/ NCT01080391 (Accesssed 12 March 2012)
85. Onyx Pharmaceuticals, Inc. Onyx Pharmaceuticals announces FDA standard review designation of carfilzomib new drug application for the treatment of relapsed and refractory multiple myeloma (December 2011). www.onyx.com/view.cfm/ 551/onyxpharmaceuticals-announces-fda-standardreview-designation-of-carfilzomib- newdrug-application-for-the-treatment-ofrelapsed-and-refractory-multiple- myeloma (Accessed 12 March 2012)
86. Keryx/AOI Pharmaceuticals, Inc. A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients. http://clinicaltrials.gov/show/ NCT01002248 (Accessed 12 March 2012)
87. Novartis Pharmaceuticals. A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma. http://clinicaltrials.gov/show/NCT01023308 (Accessed 12 March 2012)
88. Bristol-Myers Squibb. Phase III, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma. http://clinicaltrials.gov/show/NCT01239797 (Accessed 12 March 2012)